Comparative Pharmacology
Head-to-head clinical analysis: MYTELASE versus RAZADYNE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYTELASE versus RAZADYNE.
MYTELASE vs RAZADYNE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mytelase (ambenonium chloride) is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at cholinergic synapses by inhibiting its hydrolysis. This enhances neuromuscular transmission and improves muscle strength.
Galantamine is a reversible competitive acetylcholinesterase inhibitor and an allosteric modulator of nicotinic acetylcholine receptors, enhancing cholinergic function in the central nervous system.
Oral: 5–25 mg three times daily; maximum 100 mg/day. IV: 2–5 mg every 2–4 hours as needed for myasthenic crisis.
Initial dose 8 mg/day PO (4 mg twice daily) for 4 weeks; increase to 16 mg/day (8 mg twice daily) for at least 4 weeks; maintenance 16-24 mg/day (12 mg twice daily). Extended-release: initial 8 mg PO once daily; after 4 weeks increase to 16 mg once daily; if tolerated, may increase to 24 mg once daily.
None Documented
None Documented
3-4 hours (short; requires frequent dosing every 3-4 hours for myasthenia gravis management).
Terminal elimination half-life is approximately 7-8 hours in healthy adults, allowing twice-daily dosing; unchanged in mild to moderate hepatic impairment but prolonged in severe hepatic impairment.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal excretion (<5%).
Renal excretion of unchanged drug accounts for approximately 20-25% of the dose; the remainder is metabolized by the liver and excreted as metabolites in urine (about 95% total) and feces (about 5%).
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor